Yan H, Yu TN. Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough. World J Gastroenterol 2022; 28(9): 973-975 [PMID: 35317054 DOI: 10.3748/wjg.v28.i9.973]
Corresponding Author of This Article
Tu-Nan Yu, MD, PhD, Doctor, Statistician, Surgeon, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 Qingchun East Road, Hangzhou 310016, Zhejiang Province, China. 3314006@zju.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 7, 2022; 28(9): 973-975 Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.973
Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough
Han Yan, Tu-Nan Yu
Han Yan, Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Tu-Nan Yu, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Author contributions: All authors helped to prepare this manuscript; Yan H and Yu TN contributed to manuscript writing, drafting conception and design.
Conflict-of-interest statement: All authors declare that there are no conflicts of interest, and there was no fund supporting this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tu-Nan Yu, MD, PhD, Doctor, Statistician, Surgeon, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 Qingchun East Road, Hangzhou 310016, Zhejiang Province, China. 3314006@zju.edu.cn
Received: October 31, 2021 Peer-review started: October 31, 2021 First decision: December 12, 2021 Revised: January 3, 2022 Accepted: January 29, 2022 Article in press: January 29, 2022 Published online: March 7, 2022 Processing time: 122 Days and 19.2 Hours
Abstract
There remains a persistent unmet need to detect the disease nonresponse (nonDR) subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma’s radiomics-clinical nomogram shows potential for the early detection of nonDR subgroups, but it is not good enough owing to at least three limitaions, which we address in this letter to the editor. First, the study did not explore RAS/BRAF mutations, HER2 amplifications, etc. to complement the current nomogram. Second, the nomogram was not validated in left- and right-sided tumors separately. Third, the most critical factor for determining the success of adjuvant therapy should be resectability rather than tumor size shrinkage, which was used in the study.
Core Tip: There remains a persistent unmet need to detect the disease nonresponse subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma’s radiomics-clinical nomogram is currently not good enough, as the study did not explore the statuses of certain tumor genes, did not validate the nomogram in left- and right-sided tumors separately, and used tumor size shrinkage rather than resectability to judge the success of adjuvant therapy.
